LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. **(Currently amended)** A compound having the molecular structure :



wherein R_3 is selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, and a moiety -C°CR' (R' being hydrogen or C1-C6 lower alkyl);

wherein R_4 is selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, and cyanide;

wherein R_{17a} is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl, or R_{17a} and R_{17b} together are oxygen forming a keto group;

wherein R_{17b} is selected from the group consisting of hydroxyl and a group transformed on the skin into hydroxyl, or R_{17a} and R_{17b} together are oxygen forming a keto group;

wherein R_{16a} is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl;

wherein R_{16b} is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl;

wherein at least one of R_3 or R_4 is not an hydrogen;

wherein at least one of R16α, R16β and R17α is neither absent nor a hydrogen atom.

2. **(Original)** The compound selected from the group consisting of :



4-cyano-16α–methyl-16β-ethyl-1,3,5(10)-estratrien-17β-ol

and



4-cyano-16α–methyl-16β-ethyl-1,3,5(10)-estratrien-17–one.

3. **(Original)** A pharmaceutical composition comprising a pharmaceutical acceptable diluent or carrier and a therapeutically acceptable amount of an antiandrogen having the molecular structure:



wherein R_3 is selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, and a moiety -C≡CR' (R' being hydrogen or C1-C6 lower alkyl);
wherein R_4 is selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, and cyanide;
wherein $R_{17\alpha}$ is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl, or $R_{17\alpha}$ and $R_{17\beta}$ together are oxygen forming a keto group;
wherein $R_{17\beta}$ is selected from the group consisting of hydroxyl and a group transformed on the skin into hydroxyl, or $R_{17\alpha}$ and $R_{17\beta}$ together are oxygen forming a keto group;
wherein $R_{16\alpha}$ is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl;
wherein $R_{16\beta}$ is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl;
wherein at least one of R_3, or R_4 is not an hydrogen.

4. **(Currently amended)** A pharmaceutical composition comprising a pharmaceutical acceptable diluent or carrier and a therapeutically acceptable amount of an antiandrogen selected from the group consisting of :



4-cyano-16a-methyl-16b-ethyl-1,3,5(10)-estratrien-17b-ol

and



4-cyano-16a-methyl-16b-ethyl-1,3,5(10)-estratrien-17-one;

wherein at least one of R16α, R16β and R17α is neither absent nor a hydrogen atom.

5. **(Currently amended)** A method of treating or reducing the risk of developing, acne, seborrhea, hirsutism or androgenic alopecia, comprising administering to a patient in need of such treatment or reduction, a therapeutically effective amount of the compound of claim 1.

6. **(Currently amended)** The method of claim 5, further comprising administering to said patient a therapeutically effective amount of an inhibitor of type 5 17β-hydroxysteroid dehydrogenase.

7. **(Original)** The method of claim 5, further comprising administering to said patient a therapeutically effective amount of a 5α-reductase inhibitor.

8. **(Original)** The method of Claim 5, further comprising administering to said patient a therapeutically effective amount of an inhibitor of Prostate Short-Chain Dehydrogenase/Reductase 1 (PSDR1).

9. **(Original)** The method of Claim 6, further comprising administering to said patient a therapeutically effective amount of an inhibitor of Prostate Short-Chain Dehydrogenase/Reductase 1 (PSDR1).

10. **(Original)** The method of claim 7, further comprising administering to said patient a therapeutically effective amount of an inhibitor of Prostate Short-Chain Dehydrogenase/Reductase 1 (PSDR1).

11. **(Original)** The method of claim 5, further comprising administering to said patient a therapeutically effective amount of a 5α-reductase inhibitor and an inhibitor of type 5 17 -hydroxysteroid dehydrogenase.

12. **(Original)** The method of Claim 11, further comprising admininistering to said patient a therapeutically effective amount of an inhibitor of Prostate Short-Chain Dehydrogenase/Reductase 1 (PSDR1).